Amgen's earnings beat, but analysts spooked by falling product sales; Boehringer powers 2012 sales to €14.7B, an 11.4% jump;

@FiercePharma: More on GSK's first-quarter numbers to come. For now, sales down 2% to £6.5 bn. Release | Follow @FiercePharma

@EricPFierce: FDA thinks a computer system can help it identify which plants are at most risk & should top list for inspections. More | Follow @EricPFierce

> Amgen's ($AMGN) first-quarter earnings beat expectations at $1.91 per share, partly on lower taxes, but its $4.24 billion in sales fell short as several of its key products lost ground. Release | Report

> Boehringer Ingelheim posted an 11.5% increase in annual sales to about €14.7 billion in 2012, and it expects mid-single-digit growth this year, executives said during an annual year-in-review press conference. Release

> Teva Pharmaceutical Industries ($TEVA) created a new division to manage its specialty drugs and tapped Rob Koremans, currently a Teva director, to lead that business. Report

> The FDA plans a study to determine whether corrective consumer advertising actually works to change misconceptions caused by previously deficient ads. Report

> AstraZeneca ($AZN) launched its first mobile app on the corporate side, aimed at keeping investors abreast of company news and developments. Report

> Ironwood Pharmaceuticals ($IRWD) shares slid after the company posted a larger-than-expected loss and lower-than-expected revenue for the first quarter. Report

Medical Device News

@FierceMedDev: Edwards slashes projections despite Q1 growth. Story | Follow @FierceMedDev

@MarkHFierce: Some breaking news about a French device maker at BIO in Chicago. Article | Follow @MarkHFierce

 @DamianFierce: GE's diagnostics imaging is in high demand, and now the company's teaming up with Eisai on Alzheimer's. More | Follow @DamianFierce

> BIO: French device maker Eveon raising $9.1M for EU, U.S. expansion. Item

> Thermo soars on diagnostics as Life Tech deal pends. More

> GE Healthcare's Pascale Witz seeks better climate for Dx industry growth. Article

Biotech News

@FierceBiotech: Trending on FierceBiotechResearch.com: Stem cell transplant heals mouse brains with neurological deficits. More | Follow @FierceBiotech

@RyanMFierce: Israel's Treato, analyzing social for pharma, found $14.5M from OrbiMed, New Leaf and Reed Elsevier. Release | Follow @RyanMFierce

> AstraZeneca, Aussie biotech outfit ally in $240M-plus discovery deal. More

> Merck scores 'breakthrough' status from FDA for immunotherapy against melanoma. Story

> OPKO Health to acquire Prolor Biotech for $480M. Article

Drug Delivery News

@MichaelGFierce: Researchers reverse Parkinson's damage with nasal gene delivery. Article | Follow @MichaelGFierce

> New delivery combo for proven breast cancer drug boosts performance. More

> Bacteria deliver radioactive drugs to treat pancreatic cancer. Story

> AstraZeneca, Bind team up for cancer drug delivery. Item

> Civitas' inhaled Parkinson's drug promises novel delivery with positive PhII results. Article

> Cornell nanosized 'dots' for diagnostics may now deliver drugs. More

And Finally... The Mayo Clinic is spending up to $3.5 billion to go up-market, but it thinks its hometown needs to pitch in, too. Report (sub. req.)

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.